ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones

12 Jan 2026 08:00:00 By Nasdaq GlobeNewswire

Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri

08 Dec 2025 16:00:00 By Nasdaq GlobeNewswire

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5

17 Nov 2025 08:01:11 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-INFANT Phase 2 Study Evaluating ZORYVE® (roflumilast) Cream 0.05% in Infants with Atopic Dermatitis

13 Nov 2025 08:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Nov 2025 16:00:00 By Nasdaq GlobeNewswire

Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology

04 Nov 2025 08:00:01 By Nasdaq GlobeNewswire

Mother-Daughter Duo, Tori Spelling and Stella McDermott, Partner With Arcutis Biotherapeutics in the Free to Be Me Campaign, Urging People With Inflammatory Skin Conditions to Speak With Their Healthcare Provider About Long-Term Treatments

30 Oct 2025 09:15:00 By Nasdaq GlobeNewswire

Arcutis Launches ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Children Ages 2 to 5

30 Oct 2025 08:00:01 By Nasdaq GlobeNewswire

Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results

28 Oct 2025 08:30:00 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conferences

27 Oct 2025 16:00:00 By Nasdaq GlobeNewswire

Arcutis to Present New Quality of Life and Long-Term Data with ZORYVE® (roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatitis at the Fall Clinical Dermatology Conference

24 Oct 2025 08:00:00 By Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

06 Oct 2025 08:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Oct 2025 16:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025

29 Sep 2025 16:00:00 By Nasdaq GlobeNewswire

Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress

17 Sep 2025 04:00:00 By Nasdaq GlobeNewswire

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

16 Sep 2025 09:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Sep 2025 16:00:00 By Nasdaq GlobeNewswire

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5

03 Sep 2025 11:43:39 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conferences

19 Aug 2025 16:00:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Aug 2025 16:00:00 By Nasdaq GlobeNewswire